Neurocrine Biosciences, Inc. (NBIX)
Automate Your Wheel Strategy on NBIX
With Tiblio's Option Bot, you can configure your own wheel strategy including NBIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NBIX
- Rev/Share 24.1986
- Book/Share 25.4333
- PB 4.8908
- Debt/Equity 0.1765
- CurrentRatio 3.1323
- ROIC 0.1031
- MktCap 12310355862.0
- FreeCF/Share 4.9368
- PFCF 25.0109
- PE 40.5549
- Debt/Assets 0.1213
- DivYield 0
- ROE 0.1181
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NBIX | Needham | Hold | Buy | -- | $138 | April 15, 2025 |
| Upgrade | NBIX | RBC Capital Mkts | Sector Perform | Outperform | -- | $137 | April 14, 2025 |
| Initiation | NBIX | Deutsche Bank | -- | Hold | -- | $138 | Feb. 11, 2025 |
| Resumed | NBIX | Raymond James | -- | Outperform | -- | $155 | Oct. 10, 2024 |
| Upgrade | NBIX | Piper Sandler | Neutral | Overweight | $131 | $159 | Aug. 29, 2024 |
News
CPRX or NBIX: Which Is the Better Value Stock Right Now?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attractive to value investors?
Read More
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025.
Read More
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24 Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment SAN DIEGO , June 2, 2025 /PRNewswire/ -- …
Read More
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (crinecerfont) for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses.
Read More
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first …
Read More
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose - Findings to be Presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology SAN DIEGO , May 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new results from subgroup analyses of the Phase 3 CAHtalyst™ Pediatric study. The analyses showed that, consistently across all of the different subgroups analyzed, pediatric patients with classic congenital adrenal hyperplasia maintained or improved their androstenedione levels with CRENESSITY™ (crinecerfont) while reducing glucocorticoid …
Read More
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
Published: May 06, 2025 by: Investors Business Daily
Sentiment: Positive
Neurocrine Biosciences shares catapulted Tuesday on "surprising commercial momentum" for its newest drug, Crenessity.
Read More
2 Pharma Stocks Staging Big Post-Earnings Moves
Published: May 06, 2025 by: Schaeffers Research
Sentiment: Neutral
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.
Read More
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health advocate, Carnie Wilson. The campaign aims to support people struggling with the uncontrolled movements of tardive dyskinesia, an involuntary movement disorder associated with the use of antipsychotic medications, by sharing stories of courage and resilience in seeking diagnosis and treatment.
Read More
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.
Read More
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Published: April 04, 2025 by: PRNewsWire
Sentiment: Neutral
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
Read More
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
Read More
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you work in the biotech industry, you might know the name Alex Denner.
Read More
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
Read More
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Read More
About Neurocrine Biosciences, Inc. (NBIX)
- IPO Date 1996-05-23
- Website https://www.neurocrine.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Kyle W. Gano Ph.D.
- Employees 1800